Weiss Asset Management LP Buys New Shares in Janux Therapeutics, Inc. $JANX

Weiss Asset Management LP bought a new position in Janux Therapeutics, Inc. (NASDAQ:JANX) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 93,144 shares of the company’s stock, valued at approximately $1,295,000.

A number of other institutional investors have also bought and sold shares of the business. Janus Henderson Group PLC raised its holdings in Janux Therapeutics by 13.8% during the fourth quarter. Janus Henderson Group PLC now owns 5,350,453 shares of the company’s stock valued at $73,850,000 after acquiring an additional 649,341 shares during the period. State Street Corp boosted its stake in shares of Janux Therapeutics by 103.8% in the fourth quarter. State Street Corp now owns 3,853,951 shares of the company’s stock worth $53,185,000 after acquiring an additional 1,962,486 shares during the period. Vanguard Group Inc. boosted its stake in shares of Janux Therapeutics by 10.4% in the third quarter. Vanguard Group Inc. now owns 2,417,104 shares of the company’s stock worth $59,074,000 after acquiring an additional 227,676 shares during the period. Prosight Management LP grew its position in shares of Janux Therapeutics by 176.5% during the fourth quarter. Prosight Management LP now owns 2,392,523 shares of the company’s stock worth $33,017,000 after purchasing an additional 1,527,173 shares in the last quarter. Finally, Orbimed Advisors LLC grew its position in shares of Janux Therapeutics by 10.7% during the fourth quarter. Orbimed Advisors LLC now owns 1,954,426 shares of the company’s stock worth $26,971,000 after purchasing an additional 188,326 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Guggenheim lowered their price target on Janux Therapeutics from $68.00 to $58.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Evercore set a $22.00 price objective on shares of Janux Therapeutics in a report on Monday, May 11th. Wedbush reduced their price objective on shares of Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating on the stock in a research report on Friday, May 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Janux Therapeutics in a report on Monday, July 20th. Finally, Truist Financial restated a “buy” rating and set a $26.00 target price (down from $80.00) on shares of Janux Therapeutics in a research report on Thursday, June 25th. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Janux Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $38.08.

Janux Therapeutics Trading Up 1.6%

Shares of JANX stock opened at $15.57 on Tuesday. Janux Therapeutics, Inc. has a 12-month low of $12.12 and a 12-month high of $35.34. The stock’s 50-day moving average price is $14.84 and its 200-day moving average price is $14.35. The stock has a market capitalization of $949.46 million, a price-to-earnings ratio of -8.46 and a beta of 2.52.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, May 7th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.13. The firm had revenue of $3.73 million during the quarter, compared to analysts’ expectations of $4.36 million. As a group, research analysts predict that Janux Therapeutics, Inc. will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Janeen Noel Doyle sold 4,059 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total transaction of $56,947.77. Following the completion of the transaction, the insider directly owned 75,941 shares in the company, valued at approximately $1,065,452.23. This represents a 5.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Maria Dobek sold 2,038 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $14.17, for a total transaction of $28,878.46. Following the completion of the transaction, the vice president directly owned 32,270 shares of the company’s stock, valued at approximately $457,265.90. This trade represents a 5.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 7.90% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.